Uniphar plc
Full Year Trading Update and Notice of
Results
Dublin, London | 28 January 2025: Uniphar plc (the "Group" or "Uniphar"), an international
diversified healthcare services business today announces the
following unaudited trading update for the year ended 31 December
2024.
The business performed in line with
the Group's expectations for 2024 at an EPS level, while delivering
normalised free cashflow conversion above our medium-term guidance.
The Group achieved over 8% growth in organic gross profit and 12%
adjusted EPS growth.
The Group continues to maintain a
strong liquidity position, with lower than projected net
debt/EBITDA of 1.5x at year-end.
Outlook
Uniphar is well positioned to
deliver organic gross profit growth across all divisions and,
consistent with the Group's medium-term targets, is expecting
organic gross profit growth in 2025 as follows:
·
Uniphar Pharma: Double digit
·
Uniphar Medtech: High single digit
·
Uniphar Supply Chain & Retail: Low single
digit
M&A continues to play an
important role in Uniphar's growth strategy, and the Group
maintains a disciplined approach to capital allocation, while
managing an active pipeline of acquisition opportunities to further
enhance the Group's growth potential.
Ger
Rabbette, Uniphar Group Chief Executive Officer
said:
"2024 was a great year for Uniphar, with all our divisions
contributing to excellent organic growth. The results show the
positive impact that our strategy is having on our ability to grow
at pace organically. We have now delivered a 5-year EPS CAGR of
over 15%. Based on our 2024 results, we are even more
confident of reaching our €200m EBITDA target over the medium-term,
with at least 80% of our growth being organic"
Notice of Results
The Group expects to publish its
final results for the year ended 31 December 2024 at 07:00 (GMT) on
25th February 2025.
A conference call for analysts and
investors will be held at 09.00 (GMT) on 25th February
2025 to discuss the Group's final results. Analysts and investors
who wish to participate should visit www.uniphar.ie to
register.
The Company's final results press
release and presentation will also be available on the website at
07.00 (GMT) on 25th February 2025
at www.uniphar.ie.
--- ENDS ---
Contact details
|
Uniphar Group
|
Tel: +353 (0) 1 428
7777
|
|
Allan Smylie, Head of
Strategy and IR
|
|
|
|
Davy (Joint Corporate Broker, Nominated Advisor
and
Euronext Growth Listing Sponsor)
|
Tel: +353 (0) 1 679
6363
|
|
Daragh
O'Reilly
Niall
Gilchrist
Ivan Murphy
|
|
|
|
|
|
RBC Capital Markets (Joint Corporate
Broker)
|
Tel: +44 (0) 20 7653
4000
|
|
Jamil Miah
Rupert
Walford
|
|
|
|
|
|
Stifel Nicolaus Europe Limited (Joint
Corporate Broker)
|
Tel:
+44 (0) 20 7710 7600
|
|
Matt Blawat
Ben
Maddison
Francis
North
|
|
|
|
|
|
Q4 PR
|
Tel: +353 (0) 1 475
1444
|
|
Iarla Mongey, Public
Relations Advisor to Uniphar Group
|
|
About Uniphar plc
Headquartered in Dublin, Ireland,
the Uniphar Group is an international diversified healthcare
services business servicing the requirements of more than 200
multinational pharmaceutical and medical technology manufacturers
across three divisions - Uniphar Pharma, Uniphar Medtech and
Uniphar Supply Chain & Retail. The Group is active in Europe,
North America, APAC and MENA and delivers to 160+
countries.
The Company's vision is to improve
patient access to pharmaco-medical products and treatments by
enhancing connectivity between manufacturers and healthcare
stakeholders. Uniphar represents a strong combination of scale,
growth, and profitability.
Uniphar Supply Chain & Retail
Uniphar Supply Chain & Retail is
the leading pharmaceutical wholesaler in Ireland with a growing
symbol group offering of retail pharmacies. The Group's strategy
for Uniphar Supply Chain & Retail is to grow our wholesale
market share, our symbol group network and our own brand,
in-licenced and consumer products portfolio.
Uniphar Medtech
Uniphar Medtech is a leading
Pan-European medical device distributor and solutions partner. The
Group's strategy for Uniphar Medtech is to grow our service
offering across Europe and expand our addressable market by serving
new specialities and new manufacturers.
Uniphar Pharma
Uniphar Pharma operates a global
business with high value services across the lifecycle of a
pharmaceutical product. We enable pharma and biotech companies to
bring innovative medicines to global markets and provide healthcare
professionals with access to medicines they can't source through
traditional channels. Our strategy is to build a leading platform
to provide the specialist support and expertise needed to improve
access to these medicines.
